Clozapine-induced neuroleptic malignant syndrome: review and report of new cases.
The published case reports of clozapine-induced neuroleptic malignant syndrome (NMS) are reviewed, to which the authors add three, and possibly four, new cases seen in Australia, occurring in and estimated 1,250 patients exposed to the drug. The review suggests that typical NMS does occur with clozapine and that its incidence may be as common as with the classic neuroleptics. The features of clozapine-induced NMS may be somewhat different, with fewer extrapyramidal side effects and a lower rise in creatine kinase levels. The occurrence of NMS with clozapine raises important issues with regard to our understanding of the pathophysiology of the syndrome.
Sachdev
P
P
Neuropsychiatric Institute, Prince Henry Hospital, Sydney, Australia.
Kruk
J
J
Kneebone
M
M
Kissane
D
D
D000293:Adolescent; D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001315:Australia; D002648:Child; D003024:Clozapine / Q000009:adverse effects* / Q000627:therapeutic use; D003402:Creatine Kinase / Q000097:blood; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009459:Neuroleptic Malignant Syndrome / Q000209:etiology*; D009460:Neurologic Examination / Q000187:drug effects; D012559:Schizophrenia / Q000188:drug therapy*
D014150:Antipsychotic Agents; D003402:Creatine Kinase; D003024:Clozapine